Cerba Lab raises €80m for acquisition of JS Bio

By Jon Hay
24 Apr 2014

Cerba European Lab, the French clinical pathology testing business, issued an €80m high yield bond tap on Thursday to finance its acquisition of JS Bio.

Goldman Sachs was the only bookrunner on the 5.7 year (February 2020) deal, which was announced as a drive-by on Thursday morning. 

The deal is a tap of a €365m issue that Cerba sold in January 2013. The senior secured bonds are rated B2/B+/BB-.

At around midday London time, Goldman ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial